Helbig G, et al. - This inquiry was set up to assess the safety profile of autologous hematopoietic stem cell transplantation (AHSCT) in patients with systemic sclerosis. Based on the findings, researchers realized a strong need to optimize patient selection before proceeding to AHSCT in this population in order to reduce toxicity. They recommended avoiding alemtuzumab administration due to high risk of life-threatening infectious complications.